<DOC>
	<DOCNO>NCT02609529</DOCNO>
	<brief_summary>IBS common diagnosis new patient pediatric gastroenterology clinic , account 36 % new patient . Pediatric IBS patient always problem defecation , characterize either diarrhea predominant constipation predominant . About one third pediatric IBS subject d-IBS . There FDA approve treatment child d-IBS . There evidence diarrhea predominant irritable bowel syndrome d-IBS may cause mild inflammation intestinal lining . Oral serum-derived bovine immunoglobulin protein isolate ( SBI ) medical food , believe treat mild inflammation small intestine associate case d-IBS , especially arise acute gastroenteritis . It improve pain diarrhea adult d-IBS . Our aim determine SBI improve number spontaneous bowel movement child d-IBS .</brief_summary>
	<brief_title>SBI Children With d-IBS</brief_title>
	<detailed_description>The objective study determine whether improvement gastrointestinal symptom ( i.e. , number spontaneous bowel movement . abdominal pain , stool consistency , reduction stool number , flatulence , urgency , incontinence ) , laboratory parameter , and/or psychosocial measure subject d-IBS receive 3 week SBI . This randomized , double-blind , placebo-controlled , weighted , pilot study evaluate effect SBI ( 10 g per day ) , child adolescent d-IBS . The primary outcome change number spontaneous bowel movement screen week compare final week . This information gather part daily diary question . Secondary clinical outcome variable include change abdominal pain , stool consistency , flatulence , urgency , incontinence . Further clinical outcome variable change number spontaneous bowel movement treatment week compare screen week . Stool consistency assess Bristol Stool Form Scale . Secondary laboratory outcome variable include change stool calprotectin , stool lactoferrin , erythrocyte sedimentation rate , C-reactive protein , platelet count screen week final week . Secondary psychosocial outcome include data Pediatric Quality Life Inventory Gastrointestinal Symptoms , Pediatric Functional Disability Index .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Males nonpregnant female 8 year 18 year time consent . 2 . Able obtain parental legal guardian inform consent subject applicable . 3. dIBS determine ROME III criterion . A Rome III diagnosis consist recurrent abdominal pain discomfort least 2days/week last 3 month prior enrollment associate two following10 : 1 . Improvement defecation 2 . Onset associate change frequency stool 3 . Onset associate change form ( appearance ) stool . 1 . Children take pharmacologic treatment dIBS exclude . 2 . Children unable articulate symptom IBS exclude . 3 . NonEnglish speaking child exclude . 4 . Children know allergy hypersensitivity beef component SBI . 5 . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Nutrition</keyword>
</DOC>